Multiple myeloma Trials in Madrid, Spain
Conditions / Multiple myeloma / Madrid, Spain
Clinical trials for Multiple myeloma investigate a range of treatment strategies and patient populations.
151 total trials for this combination
Showing top 10 of 151 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01345019 | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma | COMPLETED | PHASE3 |
| NCT05317416 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | ACTIVE_NOT_RECRUITING | — |
| NCT05317416 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | ACTIVE_NOT_RECRUITING | — |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | COMPLETED | PHASE1 |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | RECRUITING | — |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | TERMINATED | PHASE1 |
| NCT05317416 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | ACTIVE_NOT_RECRUITING | — |
| NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | RECRUITING | — |
| NCT01239797 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | COMPLETED | PHASE3 |